Skip to main content
OpenTrials
Completed

NCT Number: NCT03087474

Treatment of Venous Thromboembolism in Real-Life Patients

In a population of patients with venous thromboembolism and treated with oral anticoagulants (OAC) in routine clinical practice in Denmark this study will describe patients treated with each OAC

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Venous Thromboembolism Cardiovascular Diseases Embolism and Thrombosis Thromboembolism Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients ≥ 18 years diagnosed with incident VTE at Danish public hospitals from 2006 through 2015
  • First-time (index) VTE will be defined as an in- or out-patient diagnosis of DVT or PE among patients redeeming a prescription for anticoagulant drugs within 30 days after index date

Exclusion criteria

  • In the analyses on type and duration of anticoagulant use, Patients with cancer will be excluded as they typically receive low molecular heparin directly from the hospital and their use of anticoagulants can therefore not be captured by redeemed prescriptions at pharmacies.

Treatment and study plan

Non-Interventional

Other

Non-Interventional

Primary outcomes

  1. Hospitalization rate in VKA patients for VTE

    Time frame: Approximately 180 months

    Hospitalization rate for first-time Venous thromboembolism (VTE) in Vitamin K antagonist (VKA) patients

  2. VTE hospitalization rate in VKA patients by sex

    Time frame: Approximately 180 months

  3. VTE hospitalization rate in VKA patients by age

    Time frame: Approximately 180 months

  4. Hospitalization rate in NOAC patients for VTE

    Time frame: Approximately 180 months

    Hospitalization rate for first-time venous thromboembolism in nonvitamin K antagonist oral anticoagulants (NOAC) patients

  5. VTE hospitalization rate in NOAC patients by sex

    Time frame: Approximately 180 months

  6. VTE hospitalization rate in NOAC patients by age

    Time frame: Approximately 180 months

  7. Duration of Treatment in NOAC patients

    Time frame: Approximately 180 months

  8. Duration of treatment in VKA patients

    Time frame: Approximately 180 months

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Official study title

Treatment of Venous Thromboembolism in Real-Life Patients: A Nationwide, Population-Based Study

Important dates

Study start
2015
Primary completion
2017
Study completion
2018
First posted
Mar 22, 2017
Registry last updated
Jul 11, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.